Publications by authors named "R J Bennie Ram John Jesudason"
Article Synopsis
- Optical pooled screening (OPS) is a method that connects images of cells with genetic changes, but it previously had limitations in its ability to analyze complex data in cancer cell lines.
- The new technology, PerturbView, improves OPS by amplifying genetic barcodes for more detailed and varied phenotype analysis across different biological systems, including stem cells and immune cells.
- PerturbView has unveiled both known and new regulatory mechanisms in immune pathways, and it can be integrated with spatial transcriptomics, enhancing the potential for comprehensive studies of cellular behaviors in complex tissue environments.
Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer understanding of therapeutically relevant SCLC subsets could identify rational combination strategies and improve outcomes. We conduct transcriptomic analyses and non-negative matrix factorization on 271 pre-treatment patient tumor samples from IMpower133 and identify four subsets with general concordance to previously reported SCLC subtypes (SCLC-A, -N, -P, and -I).
View Article and Find Full Text PDFArticle Synopsis
- T cell-dependent bispecific antibodies (TDBs) not only target tumors but also cause systemic changes that can lead to adverse events in normal organs.
- In animal studies, there was a notable accumulation of lymphocytes and activation of endothelial cells in the liver, while tumor changes were less significant.
- The research suggests that specific genes, including CD9, play a role in enhancing T cell movement into normal tissues, potentially impacting the design of safer and more effective cancer immunotherapies.
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also affect antitumor immune responses. Numerous clinical trials combining antiangiogenic drugs with immunotherapies for the treatment of cancer are ongoing, but a mechanistic understanding of how disruption of tumor angiogenesis may impact immunity is not fully discerned.
View Article and Find Full Text PDFDuring cytotoxic T cell activation, lymphocyte function-associated antigen-1 (LFA-1) engages its ligands on antigen-presenting cells (APCs) or target cells to enhance T cell priming or lytic activity. Inhibiting LFA-1 dampens T cell-dependent symptoms in inflammation, autoimmune diseases, and graft-versus-host disease. However, the therapeutic potential of augmenting LFA-1 function is less explored.
View Article and Find Full Text PDF